Lynx1 Capital (CCCC) discloses 15.4M-share C4 Therapeutics position with warrant blocker

Rhea-AI Filing Summary

Lynx1 Capital Management LP and Weston Nichols report beneficial ownership of 15,423,691 shares of C4 Therapeutics, Inc. common stock, including 8,097,000 shares issuable upon exercise of Class A and Class B warrants. Their stake represents 9.9% of the common stock, based on 110,567,222 shares outstanding as of May 1, 2026 and assuming warrant exercise subject to a 9.99% ownership blocker. Voting and dispositive power over all reported shares is shared, with no sole power reported. The filing notes that a prior Schedule 13G in February 2026 inadvertently excluded the warrants from the beneficial ownership calculation. The Lynx1 Master Fund has the right to receive dividends and sale proceeds from the reported shares.

Key Figures

Beneficially owned shares: 15,423,691 shares Shares from warrant exercise: 8,097,000 shares Beneficial ownership percentage: 9.9% +2 more

5 metrics

Beneficially owned shares 15,423,691 shares Shares of C4 Therapeutics common stock reported as beneficially owned by the Reporting Persons

Shares from warrant exercise 8,097,000 shares Common shares issuable upon exercise of Class A and Class B warrants held by the Lynx1 Fund

Beneficial ownership percentage 9.9% Percentage of C4 Therapeutics common stock class beneficially owned, subject to a 9.99% blocker

Ownership blocker threshold 9.99% Maximum ownership allowed under the 9.99% blocker on warrant exercises

Shares outstanding baseline 110,567,222 shares C4 Therapeutics common stock outstanding as of May 1, 2026, used for ownership calculation

Key Terms

beneficial owner, 9.99% Blocker, dispositive power, Schedule 13G, +1 more

5 terms

beneficial owner financial

"the beneficial owner of the securities reported herein"

A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.

9.99% Blocker financial

"Each of these Warrants is subject to a 9.99% Blocker"

dispositive power financial

"Sole Dispositive Power 0.00 8 | Shared Dispositive Power 15,423,691.00"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

Schedule 13G regulatory

"The Reporting Person's previous Schedule G filing on February 17, 2026"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

warrants financial

"shares of Common Stock issuable upon exercise of the Warrants"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

FAQ

What stake in C4 Therapeutics (CCCC) does Lynx1 Capital report?

Lynx1 Capital Management and Weston Nichols report beneficial ownership of 15,423,691 C4 Therapeutics shares, representing 9.9% of the company’s common stock, based on 110,567,222 shares outstanding as of May 1, 2026.

How many C4 Therapeutics (CCCC) shares are tied to warrants in Lynx1’s position?

Lynx1’s reported position includes 8,097,000 C4 Therapeutics shares issuable upon exercise of Class A and Class B common stock purchase warrants held by the Lynx1 Master Fund.

What is the 9.99% blocker affecting Lynx1’s CCCC ownership?

Each warrant held by Lynx1 is subject to a 9.99% blocker, limiting exercises so that post-exercise beneficial ownership does not exceed 9.99%, even though the table shows shares assuming full exercise.

On what share count is Lynx1’s 9.9% C4 Therapeutics (CCCC) ownership based?

The 9.9% beneficial ownership is calculated using 110,567,222 shares of C4 Therapeutics common stock outstanding as of May 1, 2026, as reported in the company’s Form 10-Q.

Who has the economic rights to the C4 Therapeutics (CCCC) shares reported by Lynx1?

The Lynx1 Master Fund LP has the right to receive or direct the receipt of dividends and proceeds from the sale of the C4 Therapeutics shares reported as beneficially owned.

Did Lynx1 correct any prior C4 Therapeutics (CCCC) ownership disclosure?

Yes. The filing states that a prior Schedule 13G dated February 17, 2026 inadvertently excluded the warrants, and this amendment now includes those warrant shares in beneficial ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 04:37 PM Accepted by SEC EDGAR 08/14/2026 - 04:32 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 4)

C4 Therapeutics, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

12529R107

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 12529R107

1

Names of Reporting Persons

Lynx1 Capital Management LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 15,423,691.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 15,423,691.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

15,423,691.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.99 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: Includes 8,097,000 shares of Common Stock (as defined in Item 2(a)) issuable upon exercise of Class A Common Stock purchase warrants and Class B Common Stock purchase warrants (together, the "Warrants"). Each of these Warrants is subject to a 9.99% blocker (the "9.99% Blocker"), and the percentage set forth on row (11) gives effect to the 9.99% Blocker. However, as more fully described in Item 4, the shares of Common Stock set forth on rows (6), (8) and (9) include the number of shares of Common Stock that would be issuable upon full exercise of the Warrants and does not give effect to the 9.99% Blocker. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to the 9.99% Blocker, is less than the number of shares of Common Stock reported in rows (6), (8), and (9). The Reporting Person's previous Schedule G filing on February 17, 2026 inadvertently excluded these Warrants from the Reporting Persons' beneficial ownership.

SCHEDULE 13G

CUSIP Number(s): 12529R107

1

Names of Reporting Persons

Weston Nichols

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 15,423,691.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 15,423,691.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

15,423,691.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.99 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: Includes 8,097,000 shares of Common Stock issuable upon exercise of the Warrants. Each of these Warrants is subject to the 9.99% Blocker, and the percentage set forth on row (11) gives effect to the 9.99% Blocker. However, as more fully described in Item 4, the shares of Common Stock set forth on rows (6), (8) and (9) include the number of shares of Common Stock that would be issuable upon full exercise of the Warrants and does not give effect to the 9.99% Blocker. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to the 9.99% Blocker, is less than the number of shares of Common Stock reported in rows (6), (8), and (9). The Reporting Person's previous Schedule G filing on February 17, 2026 inadvertently excluded these Warrants from the Reporting Persons' beneficial ownership.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: C4 Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 490 Arsenal Way, Suite 120, Watertown, MA 02472
Item 2.
(a)	Name of person filing: This statement is filed by: (i) Lynx1 Capital Management LP (the "Investment Manager"), a Delaware limited partnership, and the investment manager to Lynx1 Master Fund LP (the "Lynx1 Fund"), with respect to the shares of common stock, par value $0.0001 per share ("Common Stock"), of C4 Therapeutics, Inc., a Delaware corporation (the "Company"), directly held by the Lynx1 Fund; and (ii) Mr. Weston Nichols ("Mr. Nichols"), the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager, with respect to the shares of Common Stock directly held by the Lynx1 Fund. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the securities reported herein.
(b)	Address or principal business office or, if none, residence: Lynx1 Capital Management LP D81 Calle C Suite 301, PMB 1202 Dorado, PR, 00646-2051 Weston Nichols c/o Lynx1 Capital Management LP D81 Calle C Suite 301, PMB 1202 Dorado, PR, 00646-2051
(c)	Citizenship: Investment Manager - Delaware Mr. Nichols - United States of America
(d)	Title of class of securities: Common Stock, $0.0001 par value per share
(e)	CUSIP No.: 12529R107
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 110,567,222 shares of Common Stock outstanding as of May 1, 2026, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2026, filed with the Securities and Exchange Commission on May 12, 2026, and assumes the exercise of the Warrants (subject to the 9.99% Blocker) held by the Lynx1 Fund.
(b)	Percent of class: 9.9%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
	(ii) Shared power to vote or to direct the vote: The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
	(iii) Sole power to dispose or to direct the disposition of: The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
	(iv) Shared power to dispose or to direct the disposition of: The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. The Lynx1 Fund has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock reported herein.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Lynx1 Capital Management LP

Signature:	/s/ Weston Nichols
Name/Title:	By: Lynx1 Capital Management GP LLC, General Partner, By: Weston Nichols, Sole Member
Date:	08/14/2026

Weston Nichols

Signature:	/s/ Weston Nichols
Name/Title:	Weston Nichols, Individually
Date:	08/14/2026